DEFA14A: ESSA Pharma Sued Over Merger Disclosures

ESSA Pharma Inc. is facing a putative class action lawsuit alleging breach of contract and promissory estoppel related to disclosures made prior to its announced business combination with XenoTherapeutics Inc.

Summary

• A putative class action complaint was filed against ESSA Pharma Inc. on September 30, 2025, in the Superior Court of the State of California County of San Mateo.
• The lawsuit, captioned Nathan ONeil, et al. v. ESSA Pharma Inc., alleges breach of contract and promissory estoppel claims.
• These claims are based on disclosures made by the Company in its August 14, 2025 Form 8-K.
• The complaint purports to be brought on behalf of a class of all persons and entities who purchased common shares on August 25, 2025, before the Company issued its press release on that date.
• ESSA Pharma believes it has valid defenses to the claims and intends to defend the lawsuit vigorously.
• At the time of filing, the outcome of this matter and any possible related losses are not estimable or probable.
• The Company is also proceeding with a previously announced Business Combination Agreement with XenoTherapeutics Inc., under which Xeno will acquire all of ESSA Pharma's issued and outstanding common shares.

Sentiment

Score: 3

Explanation: The filing reports a class action lawsuit and lists numerous risks associated with an ongoing merger, indicating significant legal and operational uncertainty. While the company intends to defend itself, the immediate impact is negative.

Negatives

• A putative class action lawsuit has been filed against the Company, alleging breach of contract and promissory estoppel.
• The outcome of the lawsuit and any possible related losses are currently not estimable or probable, introducing significant uncertainty.
• Potential exposure or liability exists relating to a due bill communication matter that occurred on August 25, 2025.

Risks

• The completion of the Business Combination Agreement with XenoTherapeutics Inc. on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions.
• The potential for the date of the Special Meeting related to the Transaction to change.
• The outcome of the Nathan ONeil, et al. v. ESSA Pharma Inc. lawsuit or any other potential litigation relating to the Transaction.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• Disruptions from the Transaction harming the Company's business, including current plans and operations.
• The ability of the Company to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting the Company's business.
• The accuracy of the Company's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, or outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitive responses to the Transaction.
• General business risks and uncertainties as set forth in the Company's Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement and management information circular filed on August 11, 2025, and September 24, 2025.

Future Outlook

The Company is proceeding with its previously announced Business Combination Agreement with XenoTherapeutics Inc., under which Xeno will acquire all outstanding common shares. The outcome of the class action lawsuit and any possible related losses are not estimable or probable at this time, but the Company intends to vigorously defend the lawsuit.

Management Comments

• "The Company believes that it has valid defenses to the claims alleged in the Complaint and intends to defend the lawsuit vigorously, but there is no guarantee that the Company will prevail."
• "At the time of filing, the outcome of this matter and any possible related losses are not estimable or probable."

Industry Context

This filing highlights the legal and regulatory scrutiny faced by biotechnology companies, particularly during significant corporate transactions like mergers and acquisitions. Shareholder lawsuits challenging disclosures are a common risk in such events, reflecting the importance of transparent and accurate communication to investors. The ongoing merger with XenoTherapeutics suggests strategic consolidation or a pivot within the biotech sector.

Legal Proceedings

• A putative class action complaint, Nathan ONeil, et al. v. ESSA Pharma Inc., was filed on September 30, 2025, in the Superior Court of the State of California County of San Mateo.
• The complaint alleges breach of contract and promissory estoppel claims based on disclosures made in the Company's August 14, 2025 Form 8-K.
• The lawsuit purports to be on behalf of persons and entities who purchased common shares on August 25, 2025, before the Company's press release on that date.
• The Company intends to vigorously defend the lawsuit, but the outcome and possible related losses are not estimable or probable at the time of filing.

Stakeholder Impact

• Shareholders are directly impacted by the class action lawsuit (potential for damages if successful) and the ongoing Business Combination Agreement (requiring their approval, potential for share acquisition by Xeno).
• Management and employees face potential disruptions from the Transaction and challenges in retention and hiring key personnel.
• Customers and suppliers may experience adverse reactions or changes to business relationships resulting from the Transaction announcement or completion.
• Creditors are impacted by the continued availability of capital and financing, and rating agency actions.

Next Steps

• Vigorously defend against the Nathan ONeil, et al. v. ESSA Pharma Inc. class action lawsuit.
• Proceed with the Business Combination Agreement with XenoTherapeutics Inc., including obtaining required securityholder, regulatory, and court approvals.
• Hold the Special Meeting for securityholders regarding the Transaction (date potentially subject to change).
• File other documents with the SEC regarding the proposed Transaction as needed.

Key Dates

Recommendation

The company is currently facing a class action lawsuit with an uncertain outcome and unestimable potential losses, which introduces significant legal risk. However, it is also engaged in a Business Combination Agreement with XenoTherapeutics Inc. that could lead to the acquisition of its common shares. Given these conflicting and uncertain factors, a 'hold' recommendation is appropriate as investors await further clarity on both the legal proceedings and the merger's completion.

Keywords

ESSA Pharma, EPIX, Class Action Lawsuit, Merger, Acquisition, XenoTherapeutics, SEC Filing, Litigation, Biotechnology, Corporate Governance, Shareholder Lawsuit, Proxy Statement